Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
NCT07483554Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma (PDAC), sponsored by Innovent Biologics. Started Apr 2026; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07483554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483554.